Centene (CNC)
(Real Time Quote from BATS)
$62.17 USD
+0.19 (0.31%)
Updated May 31, 2023 11:42 AM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Price, Consensus and EPS Surprise
CNC 62.17 +0.19(0.31%)
Will CNC be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CNC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CNC
Centene (CNC) Down 3% Since Last Earnings Report: Can It Rebound?
The Zacks Analyst Blog Highlights PepsiCo, Salesforce, Advanced Micro Devices, Centene and Gartner
CNC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Top Analyst Reports for PepsiCo, Salesforce & AMD
Here's Why Hold Strategy is Apt for Centene (CNC) Stock Now
Select Medical (SEM) Q1 Earnings Top on Improving Profitability
Other News for CNC
Analysts Are Bullish on Top Healthcare Stocks: Centene (CNC), Intuitive Surgical (ISRG)
Unusually active option classes on open May 30th
Centene Corp. stock falls Tuesday, underperforms market
Top 5 1st Quarter Trades of Warther Private Wealth, LLC
Analysts Offer Insights on Healthcare Companies: Centene (CNC), Eli Lilly & Co (LLY) and Sarepta Therapeutics (SRPT)